A molecular approach in DRUG DEVELOPMENT for the management of cognitive dysfunction in Alzheimer’s Disease.

Cognitive decline is budding as one of the greatest health threats in the current scenario as it results in conditions like impaired attention, learning, memory, and problem solving incapability in the patient of Alzheimer’s disease. Neuroinflammation, neurodegradation and oxidative stress can lead to cognitive decline and neuronal loss. Currently, only four AChE inhibitors (tacrine, rivastigmine, donepezil and galantamine) have been approved by the FDA for the symptomatic treatment of AD. However, these acetylcholinesterase inhibitors are not devoid of side effects and have lesser CNS permeability. This instigated further development in the fields of AChEIs and antioxidants for cognitive decline as investigations in these fields seems promising and encouraging. A series of novel polyamino‐substituted‐1,4‐benzoquinone molecules were designed and synthesized against the target AChE and evaluated for their in vitro, in vivo, and ex vivo AChE inhibitory activity and antioxidant potential for the development of novel potent molecules for the management of cognitive decline.